SI0635270T1 - Obščitnični hormon in raloksifen za povečanje kostne mase - Google Patents

Obščitnični hormon in raloksifen za povečanje kostne mase

Info

Publication number
SI0635270T1
SI0635270T1 SI9430323T SI9430323T SI0635270T1 SI 0635270 T1 SI0635270 T1 SI 0635270T1 SI 9430323 T SI9430323 T SI 9430323T SI 9430323 T SI9430323 T SI 9430323T SI 0635270 T1 SI0635270 T1 SI 0635270T1
Authority
SI
Slovenia
Prior art keywords
raloxifene
bone mass
increasing bone
parathyroid hormone
pth
Prior art date
Application number
SI9430323T
Other languages
English (en)
Inventor
Janet Mary Hock
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI0635270T1 publication Critical patent/SI0635270T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9430323T 1993-07-22 1994-07-18 Obščitnični hormon in raloksifen za povečanje kostne mase SI0635270T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9648093A 1993-07-22 1993-07-22
EP94305238A EP0635270B1 (en) 1993-07-22 1994-07-18 Parathyroid hormone and raloxifene for increasing bone mass

Publications (1)

Publication Number Publication Date
SI0635270T1 true SI0635270T1 (sl) 2000-08-31

Family

ID=22257534

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430323T SI0635270T1 (sl) 1993-07-22 1994-07-18 Obščitnični hormon in raloksifen za povečanje kostne mase

Country Status (30)

Country Link
US (1) US5510370A (sl)
EP (1) EP0635270B1 (sl)
JP (1) JPH0769920A (sl)
KR (1) KR100306852B1 (sl)
CN (1) CN1105577C (sl)
AT (1) ATE189959T1 (sl)
AU (1) AU686628B2 (sl)
BR (1) BR9402902A (sl)
CA (1) CA2128376A1 (sl)
CY (1) CY2192B1 (sl)
CZ (1) CZ289648B6 (sl)
DE (1) DE69423146T2 (sl)
DK (1) DK0635270T3 (sl)
ES (1) ES2142380T3 (sl)
GR (1) GR3033492T3 (sl)
HK (1) HK1013800A1 (sl)
HU (1) HU219382B (sl)
IL (1) IL110350A (sl)
MY (1) MY124311A (sl)
NO (1) NO942708L (sl)
NZ (2) NZ264027A (sl)
PE (1) PE14595A1 (sl)
PH (1) PH30686A (sl)
PL (1) PL304348A1 (sl)
PT (1) PT635270E (sl)
RU (1) RU2155042C2 (sl)
SI (1) SI0635270T1 (sl)
TW (1) TW303299B (sl)
YU (1) YU49170B (sl)
ZA (1) ZA945249B (sl)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5502074A (en) * 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
WO1996007416A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Estrogens and parathyroid hormone for treating osteoporosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
KR19980701933A (ko) * 1995-02-06 1998-06-25 피터 쥐. 스트링거 인터루킨-6의 작용의 억제 방법
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
AU761274B2 (en) * 1996-01-29 2003-05-29 Schering Aktiengesellschaft Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1721617A3 (en) * 1997-07-22 2008-05-28 Chugai Seiyaku Kabushiki Kaisha Dental therapeutics containing parathyroid hormone
CA2306344A1 (en) * 1997-10-14 1999-04-22 Masahiko Sato Method of building and maintaining bone
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1119251A4 (en) * 1998-10-07 2004-03-24 Univ Arkansas METHOD FOR SCREENING ON ANALOG BONE THERAPY ACTIVE SUBSTANCES THAT CONTROL APOPTOSIS AND THEIR USE
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
DE60116520T2 (de) * 2000-10-10 2006-08-31 Microchips, Inc., Bedford Microchip-reservoir-vorrichtungen mit drahtloser übertragung von energie und daten
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
EA200400744A1 (ru) * 2001-11-29 2005-02-24 Джи Ти Икс, ИНК. Предупреждение и лечение остеопороза, вызванного депривацией андрогенов
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
NZ537051A (en) * 2002-06-13 2007-11-30 Wyeth Corp Use of bazedoxifene in an extended dosage treatment regimen
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
CA2566032A1 (en) * 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
AU2006208131A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) * 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
ES2666650T3 (es) 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
ATE543520T1 (de) 2007-04-13 2012-02-15 Kuros Biosurgery Ag Polymergewebeversiegelung
US8241294B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US8241363B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US8876905B2 (en) * 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
RU2012148716A (ru) * 2010-04-16 2014-05-27 Новартис Аг Способы и композиции для улучшения оссеоинтеграции имплантата
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
JP6683628B2 (ja) * 2014-06-04 2020-04-22 シーダーズ−サイナイ メディカル センター 脊椎圧迫骨折の非外科的修復のための方法
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
NO942708D0 (no) 1994-07-19
NO942708L (no) 1995-01-23
CA2128376A1 (en) 1995-01-23
CN1105577C (zh) 2003-04-16
KR100306852B1 (ko) 2001-11-30
DK0635270T3 (da) 2000-06-05
IL110350A (en) 2002-02-10
ES2142380T3 (es) 2000-04-16
YU49170B (sh) 2004-05-12
PE14595A1 (es) 1995-06-01
PT635270E (pt) 2000-07-31
AU686628B2 (en) 1998-02-12
DE69423146T2 (de) 2000-09-21
EP0635270A1 (en) 1995-01-25
ZA945249B (en) 1996-01-18
MY124311A (en) 2006-06-30
YU46794A (sh) 1997-03-07
NZ264027A (en) 1996-03-26
CZ173394A3 (en) 1995-04-12
HU9402157D0 (en) 1994-09-28
CY2192B1 (en) 2002-11-08
PH30686A (en) 1997-09-16
BR9402902A (pt) 1995-04-11
KR950002785A (ko) 1995-02-16
CN1105882A (zh) 1995-08-02
PL304348A1 (en) 1995-01-23
EP0635270B1 (en) 2000-03-01
TW303299B (sl) 1997-04-21
US5510370A (en) 1996-04-23
CZ289648B6 (cs) 2002-03-13
HK1013800A1 (en) 1999-09-10
RU94027680A (ru) 1996-11-10
HU219382B (en) 2001-03-28
JPH0769920A (ja) 1995-03-14
DE69423146D1 (de) 2000-04-06
NZ280040A (en) 1997-06-24
ATE189959T1 (de) 2000-03-15
IL110350A0 (en) 1994-10-21
AU6757794A (en) 1995-02-02
RU2155042C2 (ru) 2000-08-27
HUT67945A (en) 1995-05-29
GR3033492T3 (en) 2000-09-29

Similar Documents

Publication Publication Date Title
GR3033492T3 (en) Parathyroid hormone and raloxifene for increasing bone mass.
US4952045B1 (en) Corneal contact lens and method for treating myopea
AU6853290A (en) Composition and method for the treatment of osteoporosis in mammals
HU9401798D0 (en) Methods for the treatment of osteoporosis using bisphonates and parathyroid hormone
IL104940A0 (en) Method and composition for the treatment of osteoporosis
EP0428876A3 (en) Method for the prevention and treatment of bovine mastitis
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
GR3026568T3 (en) Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins.
TW253837B (sl)
GB2124229B (en) Composition and method for forming a5'p5'pn3'p(appnp)
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
ZA90831B (en) Method and apparatus for improvement of bone healing
SU1568996A1 (ru) Уctpoйctbo для лeчehия пepeлomob шeйkи бeдpehhoй koctи
GB8907188D0 (en) Pharmaceutical composition and method for treating psoriasis
CS135689A1 (en) Method of waste ammonium sulphate treatment
PL283664A1 (en) Therapeutical set for treating limb bone fractures by traction
GB8920107D0 (en) Method of treating toxic waste
SU1572581A1 (ru) Cпocoб лeчehия диaфизaphыx пepeлomob kocteй пpeдплeчья
GB8819259D0 (en) Method & composition for metal treatment
PL279081A1 (en) Materials treatment method, especially of furnace waste